Adare acquires Orbis for drug discovery Adare Pharmaceuticals on April 30 acquired pharmaceutical technology firm Orbis Biosciences. Financial details were not disclosed. The acquisition will enhance Adare's ability to manufacture products for the global pharmaceutical, animal health, and over-the-counter markets.
AbCellera secures COVID-19 drug development funding AbCellera Biologics has secured $175.6 million Canadian ($124.7 million U.S.) from the Canadian government's Innovation, Science, and Economic Development Strategic Innovation Fund to advance its efforts to discover antibodies for use in antiviral COVID-19 drugs.
COVID-19: A double-edged sword for the pharma industry The COVID-19 pandemic is causing major disruptions to pharmaceutical R&D activities, despite the pressing need for treatments and diagnostics for the novel coronavirus. In a new article, Ivan Gandayuwana of Strategic Directions International examines the multiple impacts COVID-19 is having on pharma. Discuss